About lexicon pharmaceuticals - LXRX
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
LXRX At a Glance
Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Boulevard
The Woodlands, Texas 77381-1160
| Phone | 1-281-863-3000 | Revenue | 49.80M | |
| Industry | Pharmaceuticals: Major | Net Income | -50,341,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 60.236% | |
| Fiscal Year-end | 12 / 2026 | Employees | 81 | |
| View SEC Filings |
LXRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.383 |
| Price to Book Ratio | 3.887 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.942 |
| Enterprise Value to Sales | 7.701 |
| Total Debt to Enterprise Value | 0.162 |
LXRX Efficiency
| Revenue/Employee | 614,851.852 |
| Income Per Employee | -621,493.827 |
| Receivables Turnover | 20.891 |
| Total Asset Turnover | 0.206 |
LXRX Liquidity
| Current Ratio | 4.883 |
| Quick Ratio | 4.87 |
| Cash Ratio | 4.612 |
LXRX Profitability
| Gross Margin | 98.203 |
| Operating Margin | -98.209 |
| Pretax Margin | -101.08 |
| Net Margin | -101.08 |
| Return on Assets | -20.828 |
| Return on Equity | -39.719 |
| Return on Total Capital | -29.652 |
| Return on Invested Capital | -24.297 |
LXRX Capital Structure
| Total Debt to Total Equity | 57.874 |
| Total Debt to Total Capital | 36.659 |
| Total Debt to Total Assets | 33.644 |
| Long-Term Debt to Equity | 52.075 |
| Long-Term Debt to Total Capital | 32.985 |